TNFRSF8 and classic Hodgkin lymphoma: Brentuximab vedotin targeting CD30 and nivolumab and pembrolizumab targeting PD-1 have demonstrated impressive single-agent activity in treating relapsed and refractory cHL and have received FDA approval for this indication.